INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER 2016

What is the investigational medicinal product dossier?

The investigational medicinal product dossier (IMPD) is a comprehensive document that provides essential information about an investigational medicinal product. It is a crucial component in the development of new drugs and is required for regulatory submissions. The dossier typically includes details such as the product's composition, manufacturing process, quality control measures, and preclinical and clinical data. It serves as a foundation for regulatory authorities to assess the safety and efficacy of the product before it can be tested in humans.

Key elements of the investigational medicinal product dossier

Several key elements are essential for a complete investigational medicinal product dossier. These include:

• Product description: Information about the active ingredients, formulation, and dosage form.
• Manufacturing details: Processes and controls used in the production of the medicinal product, including quality assurance measures.
• Preclinical data: Results from laboratory and animal studies that support the product's safety and efficacy.
• Clinical trial information: Protocols and data from clinical trials that demonstrate the product's effects in humans.
• Risk assessment: Evaluation of potential risks associated with the product and proposed mitigation strategies.

Steps to complete the investigational medicinal product dossier

Completing an investigational medicinal product dossier involves several important steps:

1. Gather all necessary data on the product, including scientific literature and previous studies.
2. Compile detailed information about the manufacturing process, including quality control measures.
3. Document preclinical and clinical trial results, ensuring clarity and accuracy.
4. Conduct a comprehensive risk assessment to identify and address potential safety concerns.
5. Review and verify all information for compliance with regulatory requirements.

Legal use of the investigational medicinal product dossier

The investigational medicinal product dossier must comply with various legal and regulatory standards to be considered valid. In the United States, the Food and Drug Administration (FDA) oversees the submission and approval process for investigational products. Compliance with the FDA's guidelines ensures that the dossier meets legal requirements for safety, efficacy, and quality. Additionally, the use of electronic signatures and digital documentation must adhere to the ESIGN and UETA acts, which establish the legal validity of electronic records and signatures.

How to obtain the investigational medicinal product dossier

Obtaining an investigational medicinal product dossier typically involves collaboration with regulatory authorities and research institutions. Researchers or companies developing a new medicinal product must prepare the dossier based on their findings and data. They may also need to consult with regulatory experts to ensure that the dossier meets all necessary requirements. Once completed, the dossier can be submitted to the relevant regulatory body for review and approval before clinical trials can commence.